Teva to Have ‘Improper Patent Listings’ Removed After Probe: FTC

Teva Pharmaceuticals is requesting that the FDA remove more than 200 “improper patent listings” from the FDA’s Orange Book in response to a challenge by the Federal Trade Commission, the FTC says in a statement.

• FTC touts improper patent listing removals as part of government effort to increase competition in drug market
  • Removals will “pave the way for greater competition for generic alternatives” for asthma, diabetes and COPD drugs, FTC says
• Read statement here
• NOTE: Teva Agrees to Pay $35 Million to Settle Inhaler Antitrust Suit

To contact the reporter on this story:
Gabriella Borter in Washington at gborter@bloomberg.net

To ...